[go: up one dir, main page]

PE20191495A1 - Piridonamidas como moduladores de canales de sodio - Google Patents

Piridonamidas como moduladores de canales de sodio

Info

Publication number
PE20191495A1
PE20191495A1 PE2019001687A PE2019001687A PE20191495A1 PE 20191495 A1 PE20191495 A1 PE 20191495A1 PE 2019001687 A PE2019001687 A PE 2019001687A PE 2019001687 A PE2019001687 A PE 2019001687A PE 20191495 A1 PE20191495 A1 PE 20191495A1
Authority
PE
Peru
Prior art keywords
pyridonamides
sodium channel
optionally substituted
channel modulators
halogen
Prior art date
Application number
PE2019001687A
Other languages
English (en)
Inventor
Sara Sabina Hadida-Ruah
Corey Anderson
Vijayalaksmi Arumugam
Iuliana Luci Asgian
Brian Richard Bear
Andreas P Termin
Jr James Philip Johnson
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PE20191495A1 publication Critical patent/PE20191495A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ink Jet (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Referido a un proceso para preparar un compuesto de formula I, o su sal farmaceuticamente aceptable, en donde R1, R2, R3 y R4 son independientemente H, halogeno, CN, alquilo C1-C6 opcionalmente sustituidos, entre otros; R5, R5', R6, R6' y R7 son independientemente H, halogeno, CN, o -X-Rx; X es un enlace o alquilo C1-C6 opcionalmente sustituido; Rx esta ausente, es H o cicloalifatico C3-C8 opcionalmente sustituido. Estos compuestos son piridonamidas moduladores de canales de sodio. Tambien se refiere su uso en el tratamiento de diversos trastornos, incluyendo dolor.
PE2019001687A 2013-01-31 2014-01-29 Piridonamidas como moduladores de canales de sodio PE20191495A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759059P 2013-01-31 2013-01-31
PCT/US2014/013652 WO2014120808A1 (en) 2013-01-31 2014-01-29 Pyridone amides as modulators of sodium channels

Publications (1)

Publication Number Publication Date
PE20191495A1 true PE20191495A1 (es) 2019-10-21

Family

ID=50073531

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001572A PE20151781A1 (es) 2013-01-31 2014-01-29 Piridonamidas como moduladores de canales de sodio
PE2019001687A PE20191495A1 (es) 2013-01-31 2014-01-29 Piridonamidas como moduladores de canales de sodio

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2015001572A PE20151781A1 (es) 2013-01-31 2014-01-29 Piridonamidas como moduladores de canales de sodio

Country Status (34)

Country Link
US (6) US9051270B2 (es)
EP (3) EP3865475A1 (es)
JP (4) JP6389194B2 (es)
KR (2) KR102295748B1 (es)
CN (2) CN108164457B (es)
AP (1) AP2015008633A0 (es)
AR (1) AR094667A1 (es)
AU (3) AU2014212509B2 (es)
BR (1) BR112015018289A2 (es)
CA (1) CA2898866C (es)
CL (1) CL2015002147A1 (es)
CY (1) CY1119163T1 (es)
DK (2) DK2953931T3 (es)
ES (2) ES2626555T3 (es)
GE (4) GEP20207177B (es)
HR (2) HRP20170787T1 (es)
HU (2) HUE053448T2 (es)
IL (2) IL240195B (es)
LT (2) LT3239134T (es)
MX (2) MX2021003687A (es)
NZ (2) NZ750187A (es)
PE (2) PE20151781A1 (es)
PH (1) PH12015501661B1 (es)
PL (2) PL3239134T3 (es)
PT (2) PT2953931T (es)
RS (2) RS61503B1 (es)
RU (1) RU2662223C2 (es)
SG (2) SG11201505953TA (es)
SI (2) SI2953931T1 (es)
SM (2) SMT202100030T1 (es)
TW (2) TWI714967B (es)
UA (1) UA120589C2 (es)
UY (1) UY35288A (es)
WO (1) WO2014120808A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933236B2 (en) 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
MX2014005297A (es) 2011-10-31 2014-09-11 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
WO2013064984A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
CN104797555B (zh) 2012-07-06 2017-12-22 基因泰克公司 N‑取代的苯甲酰胺及其使用方法
RU2683788C2 (ru) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов
DK2953931T3 (en) * 2013-01-31 2017-06-06 Vertex Pharma Pyridonamides as sodium channel modulators
HK1213476A1 (zh) 2013-03-14 2016-07-08 基因泰克公司 取代的三唑並吡啶及其使用方法
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
MX364155B (es) 2013-07-19 2019-04-12 Vertex Pharma Sulfonamidas como moduladores de canales de sodio.
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
PL3080134T3 (pl) 2013-12-13 2019-01-31 Vertex Pharmaceuticals Incorporated Proleki pirydonoamidów nadające się do stosowania jako modulatory kanałów sodowych
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3297989A1 (en) 2015-05-22 2018-03-28 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
RU2018115718A (ru) 2015-09-28 2019-10-28 Дженентек, Инк. Терапевтические соединения и способы их применения
MA43304A (fr) 2015-11-25 2018-10-03 Genentech Inc Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
WO2017140728A1 (en) 2016-02-15 2017-08-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Taf1 inhibitors for the therapy of cancer
US20170239183A1 (en) * 2016-02-23 2017-08-24 PixarBio Corporation COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
CA3039853A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
CN110740993B (zh) * 2017-05-16 2023-09-01 沃泰克斯药物股份有限公司 用作钠通道调节剂的氘代吡啶酮酰胺及其前药
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
CN111918650A (zh) 2018-02-12 2020-11-10 沃泰克斯药物股份有限公司 治疗疼痛的方法
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
WO2019191702A1 (en) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Substituted hydro-pyrido-azines as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
EP3873468A4 (en) 2018-11-02 2022-10-26 Merck Sharp & Dohme LLC 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
MA54076A (fr) 2018-11-02 2022-02-09 Merck Sharp & Dohme 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MX2021007970A (es) * 2019-01-04 2021-08-16 Jiangsu Hengrui Medicine Co Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
TW202043200A (zh) * 2019-01-25 2020-12-01 大陸商江蘇恆瑞醫藥股份有限公司 ２－側氧基－１，２－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
BR112021014178A2 (pt) * 2019-02-20 2021-09-21 Jiangsu Hengrui Medicine Co., Ltd. Derivado de pró-fármaco de 6-oxo-1,6-diidropiridazina, método de preparação para o mesmo e aplicação do mesmo na medicina
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2021018165A1 (zh) * 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用
TW202115038A (zh) * 2019-08-19 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
CN112390745B (zh) * 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
JP2022548104A (ja) * 2019-09-12 2022-11-16 オリオン コーポレーション ピリジン窒素酸化物及びその製造方法と使用
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CN113045487B (zh) * 2019-12-27 2025-01-17 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN114437062B (zh) * 2020-04-30 2024-05-17 成都海博为药业有限公司 一种可作为钠通道调节剂的化合物及其用途
GEP20257750B (en) 2020-06-17 2025-03-25 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
JP2023530319A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
CN111808019B (zh) * 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114031518B (zh) 2020-12-08 2023-08-18 成都海博为药业有限公司 一种苄胺或苄醇衍生物及其用途
TWI827037B (zh) 2021-05-07 2023-12-21 美商默沙東有限責任公司 作為nav1.8抑制劑之環烷基3-側氧基哌甲醯胺及環雜烷基3-側氧基哌甲醯胺
MX2023014376A (es) 2021-06-04 2024-03-04 Vertex Pharma Formas de dosificación sólidas y regímenes de dosificación que comprenden (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metoxi-fenil)-4,5-d imetil-5-(trifluorometil) tetrahidrofuran-2- carbonil]amino]piridi na-2-carboxamida.
HRP20251504T1 (hr) 2021-06-04 2026-01-02 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kao modulatori natrijevih kanala
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
JP2024522293A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしての置換テトラヒドロフラン類似体
UY39881A (es) 2021-08-02 2023-06-15 Eurofarma Laboratorios S A “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS”
UY39882A (es) 2021-08-02 2023-06-15 Eurofarma Laboratorios S A COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
CN116655497B (zh) * 2022-02-25 2025-06-03 中国科学院上海药物研究所 脒类衍生化合物及其制备方法和用途
JP2025514800A (ja) 2022-04-22 2025-05-09 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
AU2023256603A1 (en) 2022-04-22 2024-11-07 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
EP4511117A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
EP4514789A1 (en) 2022-04-25 2025-03-05 SiteOne Therapeutics, Inc. <sup2/>? <sub2/>?v?bicyclic heterocyclic amide inhibitors of na1.8 for the treatment of pain
WO2023207949A1 (zh) * 2022-04-25 2023-11-02 中国科学院上海药物研究所 并环类化合物及其应用
IL321269A (en) 2022-12-06 2025-08-01 Vertex Pharma Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
AR131658A1 (es) 2023-01-30 2025-04-16 Eurofarma Laboratorios S A Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits
AR131690A1 (es) 2023-01-30 2025-04-23 Eurofarma Laboratorios S A COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS
AR131715A1 (es) 2023-01-30 2025-04-23 Eurofarma Laboratorios S A AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS
EP4660182A1 (en) 2023-01-30 2025-12-10 Eurofarma Laboratórios S.A. Nav1.7- and/or nav1.8-inhibiting aryl pyridine compounds, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
WO2024159287A1 (pt) 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Hidroxamatos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
AU2024257755A1 (en) 2023-04-19 2025-11-13 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nav1.8 inhibitors, preparation method therefor and use thereof
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH598252A5 (es) * 1974-01-04 1978-04-28 Hoffmann La Roche
GB1447583A (en) * 1974-02-04 1976-08-25 Ici Ltd Xanthene derivatives
US4086350A (en) * 1974-11-06 1978-04-25 Smithkline Corporation Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
GB1543964A (en) * 1976-04-08 1979-04-11 Ici Ltd Method of antagonising herbicides on soyabean and cotton
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
JP3285391B2 (ja) * 1992-09-01 2002-05-27 日本化学工業株式会社 ２−フェノキシ安息香酸の製造法
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU7712000A (en) 1999-09-24 2001-04-24 Johns Hopkins University School Of Medicine, The Methods for identifying an agent that corrects defective protein folding
JP2003034671A (ja) * 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
EA008008B1 (ru) * 2002-02-14 2007-02-27 Фармация Корпорейшн Замещённые пиридиноны в качестве модуляторов мар-киназы р38
CA2539227A1 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
JP4116058B2 (ja) * 2003-09-03 2008-07-09 ファイザー株式会社 プロスタグランジンｅ２拮抗薬としてのフェニルまたはピリジルアミド化合物
EA200700099A1 (ru) 2004-07-23 2007-08-31 Пфайзер Инк. Производные пиридина
AU2006254809B2 (en) 2005-06-09 2012-03-15 Vertex Pharmaceuticals Incorporated Indane derivatives as modulators of ion channels
RU2008113836A (ru) 2005-09-09 2009-10-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов
CN101365690A (zh) 2005-10-12 2009-02-11 沃泰克斯药物股份有限公司 作为电压门控离子通道调控剂的联苯衍生物
NZ596413A (en) * 2006-04-11 2013-03-28 Vertex Pharma Phenyl-sulfinyl-sulfamoylphenyl-benzamide derivatives that inhibit voltage-gated sodium channels
GEP20125379B (en) * 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
JP2010528035A (ja) 2007-05-25 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節物質およびその使用
JP5436434B2 (ja) 2007-10-11 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なアミド
US8779197B2 (en) * 2007-10-11 2014-07-15 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
WO2009049180A2 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
JP5552430B2 (ja) * 2007-10-31 2014-07-16 メルク・シャープ・アンド・ドーム・コーポレーション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
MX2011006843A (es) 2008-12-23 2011-08-04 Hoffmann La Roche Dihidropiridona-amidas como moduladores de p2x7.
CN102448937A (zh) * 2009-05-29 2012-05-09 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
AR077033A1 (es) * 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
US8883782B2 (en) * 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2012050918A2 (en) * 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
US8916565B2 (en) 2011-02-02 2014-12-23 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
WO2012112462A1 (en) * 2011-02-15 2012-08-23 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
JP5940562B2 (ja) 2011-02-18 2016-06-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド
WO2012125613A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2012122716A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
MA35050B1 (fr) * 2011-03-29 2014-04-03 Sanofi Sa Formulation d'otamixaban ayant une stabilité améliorée
WO2013021535A1 (ja) 2011-08-10 2013-02-14 三菱電機株式会社 誘導加熱調理器及びそのプログラム
CN102584774B (zh) * 2011-12-22 2014-08-06 合肥工业大学 一种呫吨酮类衍生物及其用途
PT2822953T (pt) 2012-03-06 2017-04-06 Pfizer Derivados macrocíclicos para o tratamento de doenças proliferativas
CN102659628B (zh) * 2012-04-26 2014-07-02 四川大学 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂
DK2953931T3 (en) 2013-01-31 2017-06-06 Vertex Pharma Pyridonamides as sodium channel modulators
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
RU2683788C2 (ru) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов
AU2014212431B2 (en) 2013-01-31 2018-04-05 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
MX364155B (es) 2013-07-19 2019-04-12 Vertex Pharma Sulfonamidas como moduladores de canales de sodio.
PL3080134T3 (pl) 2013-12-13 2019-01-31 Vertex Pharmaceuticals Incorporated Proleki pirydonoamidów nadające się do stosowania jako modulatory kanałów sodowych
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
CN111918650A (zh) 2018-02-12 2020-11-10 沃泰克斯药物股份有限公司 治疗疼痛的方法

Also Published As

Publication number Publication date
US9051270B2 (en) 2015-06-09
KR20150112031A (ko) 2015-10-06
WO2014120808A9 (en) 2015-05-14
TW201443019A (zh) 2014-11-16
HRP20210349T1 (hr) 2021-04-16
CN105026373B (zh) 2018-03-30
HUE053448T2 (hu) 2021-06-28
IL269964B1 (en) 2025-09-01
US20170037009A1 (en) 2017-02-09
IL240195B (en) 2019-10-31
EP3865475A1 (en) 2021-08-18
KR102227592B1 (ko) 2021-03-15
ES2857687T3 (es) 2021-09-29
GEP20207177B (en) 2020-11-10
HUE033370T2 (en) 2017-11-28
MX2021003687A (es) 2023-01-25
NZ750187A (en) 2020-09-25
RS61503B1 (sr) 2021-03-31
US20140213616A1 (en) 2014-07-31
IL269964A (en) 2019-11-28
AP2015008633A0 (en) 2015-07-31
PH12015501661A1 (en) 2015-10-19
CN105026373A (zh) 2015-11-04
UY35288A (es) 2014-08-29
CY1119163T1 (el) 2018-02-14
DK3239134T3 (da) 2021-02-22
GEP20217286B (en) 2021-08-25
JP6741704B2 (ja) 2020-08-19
US9393235B2 (en) 2016-07-19
DK2953931T3 (en) 2017-06-06
JP2021001232A (ja) 2021-01-07
RU2018126184A3 (es) 2021-07-26
PL3239134T3 (pl) 2021-06-14
CA2898866C (en) 2023-03-07
TW201943701A (zh) 2019-11-16
EP3239134B1 (en) 2020-12-23
LT2953931T (lt) 2017-07-25
RU2018126184A (ru) 2019-03-12
JP2016506963A (ja) 2016-03-07
KR20210029848A (ko) 2021-03-16
JP6389194B2 (ja) 2018-09-12
EP2953931A1 (en) 2015-12-16
KR102295748B1 (ko) 2021-09-01
CN108164457A (zh) 2018-06-15
EP2953931B1 (en) 2017-03-01
AU2020204425A1 (en) 2020-07-23
PE20151781A1 (es) 2015-12-02
SMT202100030T1 (it) 2021-03-15
RS56015B1 (sr) 2017-09-29
HRP20170787T1 (hr) 2017-08-11
MX2015009602A (es) 2015-11-25
US20190248745A1 (en) 2019-08-15
HK1244269A1 (en) 2018-08-03
HK1217693A1 (en) 2017-01-20
GEAP202113922A (en) 2021-02-25
GEAP202014909A (en) 2020-07-10
AU2018214105B2 (en) 2020-04-02
TWI714967B (zh) 2021-01-01
SI2953931T1 (sl) 2017-08-31
PH12015501661B1 (en) 2020-10-16
JP2018104453A (ja) 2018-07-05
SI3239134T1 (sl) 2021-03-31
TWI655187B (zh) 2019-04-01
RU2015136795A (ru) 2017-03-10
JP2019089861A (ja) 2019-06-13
LT3239134T (lt) 2021-02-25
WO2014120808A1 (en) 2014-08-07
AU2014212509A1 (en) 2015-08-06
MX383688B (es) 2025-03-14
NZ710270A (en) 2020-09-25
US10738009B2 (en) 2020-08-11
WO2014120808A8 (en) 2015-09-11
AR094667A1 (es) 2015-08-19
PT3239134T (pt) 2021-01-28
RU2662223C2 (ru) 2018-07-25
CA2898866A1 (en) 2014-08-07
SMT201700256T1 (it) 2017-09-07
US20150246028A1 (en) 2015-09-03
GEAP201414909A (es) 2020-07-10
IL240195A0 (en) 2015-09-24
US20210047271A1 (en) 2021-02-18
PT2953931T (pt) 2017-06-14
PL2953931T3 (pl) 2017-09-29
US11673864B2 (en) 2023-06-13
CN108164457B (zh) 2021-07-09
UA120589C2 (uk) 2020-01-10
US20180016235A1 (en) 2018-01-18
BR112015018289A2 (pt) 2017-07-18
CL2015002147A1 (es) 2016-06-03
ES2626555T3 (es) 2017-07-25
SG11201505953TA (en) 2015-08-28
SG10201706206PA (en) 2017-08-30
IL269964B2 (en) 2026-01-01
AU2014212509B2 (en) 2018-05-10
EP3239134A1 (en) 2017-11-01
AU2018214105A1 (en) 2018-08-30
US9758483B2 (en) 2017-09-12
AU2018214105B9 (en) 2020-04-23
US10087143B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
AR082201A1 (es) Bencenosulfonamidas utiles como inhibidores del canal de sodio
ECSP16025201A (es) Profármacos de amidas de piridona útiles como moduladores de canales de sodio
MX2015009591A (es) Amidas como moduladores de canales de sodio.
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
ES2620379T3 (es) Quinolina y quinoxalina amidas como moduladores de canales de sodio
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
UA109220C2 (uk) Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
EA200870196A1 (ru) Индолсульфонамидные модуляторы рецепторов прогестерона
PE20150400A1 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
PE20151651A1 (es) Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina
PE20121639A1 (es) Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.
EA201592252A1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
PE20141211A1 (es) Moduladores receptores de hormonas nucleares
WO2015100092A3 (en) 7-beta analogs of orvinols